Gastroprotection With Proton-Pump Inhibitors in High-Risk Cardiovascular Patients: Who to Target and for How Long?

Expert Opinion on Drug Safety - United Kingdom
doi 10.1080/14740338.2016.1227790
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Risks of Proton Pump Inhibitors for Patients With Cirrhosis: The Controversy Remains

Hepatology
MedicineHepatology
2017English

Letter: Proton Pump Inhibitors and the Risk of Hepatocellular Carcinoma

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Optimizing Cardiovascular and Chemopreventive Benefits of Aspirin: What Role for the Proton-Pump Inhibitors?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2005English

Antiplatelet Drug Interactions With Proton Pump Inhibitors

Expert Opinion on Drug Metabolism and Toxicology
MedicineToxicologyPharmacology
2013English

Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk Among Patients on Hemodialysis

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2018English

Proton Pump Inhibitors in Kidney Disease

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2018English

Use of Proton Pump Inhibitors and Subsequent Risk of Celiac Disease

Digestive and Liver Disease
HepatologyGastroenterology
2014English

Prognosis of Concomitant Users of Clopidogrel and Proton-Pump Inhibitors in a High-Risk Population for Upper Gastrointestinal Bleeding

BMC pharmacology & toxicology
MedicinePharmacology
2014English

Proton Pump Inhibitors and Gastric Neoplasia

Gut
Gastroenterology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy